[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ISISPHARMA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100633036","dermocosmetic-treatment-for-facial-redness-in-rosacea-with-or-without-laser-therapy-100633036",false,"NCT07521462","Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy","Impact of Using a Dermocosmetic Product as Monotherapy or as an Adjunct to Laser Treatment on Redness Associated With Erythematotelangiectatic Rosacea: a Comparative Study Versus Placebo.","Inclusion Criteria:\n\n* Gender: male or female\n* Age: \\> 18 years -Patients with mild to severe erythro-couperotic rosacea (stage 2, 3, or 4 - TRoSA scale, section 2.2.3.1)\n* Patients wishing to undergo vascular laser treatments for their rosacea\n* Patients who have provided informed consent\n\nExclusion Criteria:\n\n* Pregnant patients or patients with a positive urine pregnancy test at the initial visit\n* Patients with another condition in the study area.\n* Patients who have received laser treatment for the same condition within the previous 12 months.\n* Patients with another form of rosacea (e.g., papules and pustules, ocular rosacea, etc.).\n* Patients using another anti-redness product on the face during the study.\n* Patients who have taken photosensitizing treatments during the month prior to study enrollment.\n* Patients taking or having taken oral isotretinoin within 6 months prior to study enrollment.\n* Patients enrolled in another study.\n* Adult patients under a legal guardianship arrangement (guardianship, conservatorship, judicial protection).\n* Patients not covered by social security.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this clinical study is to evaluate the effectiveness and safety of a dermocosmetic product in reducing facial redness and visible blood vessels associated with erythematotelangiectatic rosacea.\n\nInvestigators will compare the dermocosmetic product to a placebo applied to opposite sides of the face, when used alone and in combination with laser treatment.\n\nParticipants will apply the products twice daily for 2 month followed by continued use in combination with laser treatment, and will attend regular clinical visits for assessments and questionnaires.",[26,27],"Rosacea, Erythematotelangiectatic","Rosacea Subtype 1 (Erythematotelangiectatic)",[29,30,31,32],"Erythematotelangiectatic Rosacea","Telangiectasia","Dermocosmetic","Laser Therapy","NOT_YET_RECRUITING","2026-04-03",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":20},"2026-09-01",{"date":41,"type":20},"2027-06-30",{"name":43,"class":44},"ISISPHARMA","INDUSTRY",""]